ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4743

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

2 sessions
ACC.24 Late-breaking Science Wrap Up Watch now
What's Hot at ACC.24? Late-breaking Science Preview Watch now

Part 2

Late-Breaker Discussion Series

Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.  

4 sessions
Late-Breaker Discussion: The EMPACT-MI Trial Watch now
Late-Breaker Discussion: The AEGIS-II Trial Watch now
Late-Breaker Discussion: The RELIEVE-HF Trial Watch now
Late-Breaker Discussion: The ARISE-HF Trial Watch now

Part 3

Expert Interviews

Expert Interviews conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

12 sessions
Gamification and Financial Incentives to Increase PA Among Patients at Elevated Cardiovascular Risk Watch now
Zilbesiran in Patients With Hypertension: KARDIA-2 Watch now
Olezarsen in Adults with Hypertriglyceridemia and ASCVD and/or Severe Hypertriglyceridemia Watch now
Lerodalcibep in Patients With High Risk For Cardiovascular Disease on Stable Lipid-Lowering Therapy Watch now
Chelation Therapy in Post-MI Pts with Diabetes: TACT2 Watch now
Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF Watch now
Self-Expanding vs Balloon Expandable TAVR: The SMART Trial Watch now
Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT Watch now
Technology-Assisted Nonprescription Rosuvastatin: TACTiC Watch now
Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC Watch now
TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6 Watch now
Periprocedural Cerebral Embolisms and Catheter Ablation of AF: The Embo-Abl Study Watch now

Part 4

Highlights

2 sessions
Artificial Intelligence in Cardiology: What You Need to Know in 2024 Watch now
Weight Loss Medications: What You Need to Know in 2024 Watch now

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

1 session
Coming Soon Watch now

About the episode

ACC.24 — Investigator, Dr Steven Nissen joins us onsite to discuss the findings of a trial designed to evaluate the extent to which participants could safely and effectively select, purchase and use rosuvastatin calcium 5mg for a 6-month trial period (NCT04964544).

The TACTiC trial is a single-arm interventional, phase III self-selection and actual use study implementing a technology assisted tool within a web app. Around 1220 patients were enrolled in the study, with 1196 participants proceeding to the use phase. Primary outcome measures included the percentage of participants with an overall correct initial TASS outcome at the initial self selection, an overall correct final use outcome at the final use assessment, and percent baseline change in verified LDL-C. 

Findings first revealed at ACC showed that overall concordance between consumers and clinicians for initial self-selection was 90.7% (95% CI, 88.9 to 92.3). Final use assessment was concordant in 98.1% (95% CI, 97.1 to 98.8), with a mean change in LDL-C of -35.5% (95% CI, -36.6 to -34.3). Participants also had a high level of adherence, with no major safety issues.

Interview Questions:

  1. What is the importance of this study?
  2. What was the study design and enrolment?
  3. Could you tell us more about how the participant would use the web app?
  4. What were the key findings?
  5. Based on these findings, what are the implications for clinical practice?
  6. What are the knowledge gaps?
  7. What are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

Faculty Biographies

Steven E Nissen

Steven E Nissen

Cleveland Clinic, Cleveland, US

Dr. Steven E. Nissen, an esteemed American cardiologist, researcher, and patient advocate, has left an indelible mark in the field of cardiology. Formerly the chairman of cardiovascular medicine at the renowned Cleveland Clinic in Ohio, Dr. Nissen brings a wealth of experience and expertise to his roles.

Joining the Cleveland Clinic in 1992, Dr. Nissen held key positions, including Vice-Chairman of the Department of Cardiology, Section Head of Clinical Cardiology, and Director of the Coronary Intensive Care Unit. In his most recent role, he served as the Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), overseeing multi-center clinical trials. Dr. Nissen continues to contribute periodically in the Cardiac Critical Care Unit, showcasing his ongoing commitment to patient care.

A highly accomplished academic, Dr. Nissen graduated from the Webb School of California before pursuing his undergraduate degree at the University of Michigan. He…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.